Bioatla, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Bioatla, Inc. (Nasdaq: BCAB) on March 11, 2025. The report discloses compensatory arrangements for Named Executive Officers (NEOs) approved by the Compensation Committee and the Board of Directors in mid-March 2025, relating to performance in fiscal year 2024.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation details:
- Cash Bonuses (FY 2024):
- Richard Waldron (CFO): $120,160
- Eric Sievers (CMO): $127,555
- Jay Short (CEO): $275,558
- Equity Awards (RSUs):
- Richard Waldron: 100,000 RSUs
- Eric Sievers: 175,000 RSUs
- Jay Short: 431,000 RSUs
Material Changes
The filing reports the approval of specific cash bonuses and equity grants. These awards represent 62.5% of the target bonus for each executive, indicating that the company achieved a portion, but not all, of its 2024 clinical development, R&D, and business objectives.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, financial outlook, or discussion of risks and contingencies. The compensation is explicitly tied to the achievement of 2024 milestones. The RSU grants vest over a four-year period, with 25% vesting on the first anniversary and the remainder vesting quarterly thereafter, contingent on continued service.
Investor Verification Checklist
- Verify the specific clinical and R&D milestones achieved in 2024 that triggered the 62.5% bonus payout.
- Confirm the total number of shares outstanding and the dilution impact of the 706,000 newly granted RSUs.
- Review the 2020 Equity Incentive Plan (EIP) terms to understand the vesting acceleration clauses or forfeiture conditions.
- Check subsequent filings for the actual payout dates of the cash bonuses.